Phase 2 Field Study Of Travelers' Diarrhea Vaccine Promising
Travelers' Diarrhea Vaccine
Abstract detailing efficacy and safety results from Iomai Corporation's double-blind Phase 2 field study of a patch-based vaccine for travelers' diarrhea has been accepted as a "late breaker" presentation.
The abstract, "Transcutaneous Immunization with the Heat Labile Toxin (LT) of Enterotoxigenic Escherichia coli (ETEC) Protects in a Phase 2 Field Trial in Travelers to Guatemala and Mexico," will be presented by Gregory Glenn, M.D., Iomai's chief scientific officer, on Tuesday, Sept. 18, during the session on "Vaccines and Pediatric Infections." The session will be held from 1:30 to 4 p.m.
About Travelers' Diarrhea
This year, approximately 55 million international travelers will visit countries where bacteria that cause travelers' diarrhea are endemic, particularly Africa, Asia and Latin America, and about 20 million of those travelers will develop travelers' diarrhea.
Travelers' diarrhea (TD) is caused by ingestion of pathogens in contaminated food and water. Of the 54 million travelers to endemic areas, an estimated 17 million will contract TD, making it one of the most common illnesses in travelers. Symptoms last for 3 to 5 days, and 55 percent of subjects who become ill have more than six stools daily, with an average of 18 total stools per episode. TD is often accompanied by nausea, vomiting and cramping and can result in severe dehydration, mimicking the symptoms of cholera. Although generally self-limited, TD is often accompanied by prostration and can require hospitalization, often in settings where health care is inadequate. Additionally, 10 to 30 percent of travelers who contract diarrhea also develop a more chronic condition, irritable bowel syndrome.